Catalog exploration ranks

StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.

Derivative structure exploration tiers

Rule-based Catalog Exploration Score from SMILES similarity, approved/clinical tags, family network size, and SAR metadata. It does not predict efficacy, safety, or development success.

전체 도메인 신경 하이라이트 Chemometric Deep Analysis →

Core 후보 59파생 후보 24041 패밀리

Core 구조 파생 구조 구조 탐색

MedMedium exploration priority2

Upper-mid Exploration Score percentile (X-A bin)

High exploration priority	2D	Structure	Class	Exploration Score	Factors
Med		Enlicitide (Lipfendra) PCSK9 inhibitor chemical & modality series · Drug	PCSK9 / LDL-C	96	Drug · SMILES 확보 · 승인·상용 · Core 유사 100%
Med		Alirocumab (Praluent) PCSK9 inhibitor chemical & modality series · Drug	PCSK9 / LDL-C	91	Drug · SMILES 확보 · 승인·상용 · Core 유사 78%

MedEnlicitide (Lipfendra)

PCSK9 inhibitor chemical & modality series · Drug · PCSK9 / LDL-C

Drug · SMILES 확보 · 승인·상용 · Core 유사 100%

MedAlirocumab (Praluent)

PCSK9 inhibitor chemical & modality series · Drug · PCSK9 / LDL-C

Drug · SMILES 확보 · 승인·상용 · Core 유사 78%

MedMedium exploration priority2

Mid-pool Exploration Score (X-B bin)

High exploration priority	2D	Structure	Class	Exploration Score	Factors
Med		Evolocumab (Repatha) PCSK9 inhibitor chemical & modality series · Drug	PCSK9 / LDL-C	91	Drug · SMILES 확보 · 승인·상용 · Core 유사 78%
Med		MK-0616 (enlicitide development code) PCSK9 inhibitor chemical & modality series · Derivative	PCSK9 / LDL-C	78	Derivative · SMILES 확보 · 임상 · Core 유사 100%

MedEvolocumab (Repatha)

PCSK9 inhibitor chemical & modality series · Drug · PCSK9 / LDL-C

Drug · SMILES 확보 · 승인·상용 · Core 유사 78%

MedMK-0616 (enlicitide development code)

PCSK9 inhibitor chemical & modality series · Derivative · PCSK9 / LDL-C

Derivative · SMILES 확보 · 임상 · Core 유사 100%

LowLow exploration priority4

Lower Exploration Score — still listed for inspection (X-C bin)

High exploration priority	Structure	Class	Exploration Score	Factors
Low	Inclisiran (Leqvio) PCSK9 inhibitor chemical & modality series · Drug	PCSK9 / LDL-C	74	Drug · SMILES 확보 · 승인·상용
Low	Lerodalcibep (LIB003) PCSK9 inhibitor chemical & modality series · Drug	PCSK9 / LDL-C	66	Drug · SMILES 확보 · 임상
Low	Oral PCSK9i amide SAR analog PCSK9 inhibitor chemical & modality series · Derivative	PCSK9 / LDL-C	63	Derivative · SMILES 확보 · Core 유사 86%
Low	Oral PCSK9i fluoro-macrocycle analog PCSK9 inhibitor chemical & modality series · Derivative	PCSK9 / LDL-C	63	Derivative · SMILES 확보 · Core 유사 86%

LowInclisiran (Leqvio)

PCSK9 inhibitor chemical & modality series · Drug · PCSK9 / LDL-C

Drug · SMILES 확보 · 승인·상용

LowLerodalcibep (LIB003)

PCSK9 inhibitor chemical & modality series · Drug · PCSK9 / LDL-C

Drug · SMILES 확보 · 임상

LowOral PCSK9i amide SAR analog

PCSK9 inhibitor chemical & modality series · Derivative · PCSK9 / LDL-C

Derivative · SMILES 확보 · Core 유사 86%

LowOral PCSK9i fluoro-macrocycle analog

PCSK9 inhibitor chemical & modality series · Derivative · PCSK9 / LDL-C

Derivative · SMILES 확보 · Core 유사 86%

Exploration score method

StructureMoa ranks are a rule-based Exploration Score. An LLM does not predict activity or efficacy. Role, SMILES, and relation signals inside each family are summed and cut into High / Medium / Low exploration priority.

Core tab

scaffold / payload / linker role weights
family center-compound bonus
SMILES source (db · known · pubchem · inherited)
relation-edge count and derived-child count

Derivative tab

drug / derivative / adc candidates
similarity to family center via Morgan fingerprint, radius 2, 2048 bits, Tanimoto
approved / clinical catalog-tag bonuses
ADC / payload tags

Explore tab

sparse SAR, cross-scaffold pairs, expansion leaves
weakly linked nodes and approved-tag neighborhood gaps
relation graph + stored Morgan fingerprints
category filters

Exploration-priority bins

High (X-S): top ~12%
Medium (X-A/X-B): ~12–62%
Low (X-C): remainder (pools under 5 compounds stay Medium)

Internal exploration metric based on catalog and structural signals. Not a prediction of efficacy, safety, potency, or development success.

Full methodology

평가 시각: 2026. 9. 11. 오전 4:41:20 · 캐시 5분 · 전체 패밀리